Scandinavian ChemoTech AB Series B Total Assets
Scandinavian ChemoTech AB Series B total assets. Based on the latest financial reports, Scandinavian ChemoTech AB Series B (CMOTEC-B) holds total assets worth Skr11.01 Million SEK (≈ $1.18 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Scandinavian ChemoTech AB Series B stock valuation for the company's overall valuation and market capitalisation.
Total Assets of Scandinavian ChemoTech AB Series B (2013–2025)
Total assets of Scandinavian ChemoTech AB Series B from 2013 to 2025. This chart illustrates how Scandinavian ChemoTech AB Series B's total assets have evolved over time, based on quarterly financial data. See CMOTEC-B share price today for real-time trading data and today's change.
Scandinavian ChemoTech AB Series B - Asset Composition Analysis
Scandinavian ChemoTech AB Series B Total Assets Breakdown (December 2025)
Scandinavian ChemoTech AB Series B total assets breakdown as of December 2025. Scandinavian ChemoTech AB Series B's total assets of Skr11.01 Million consist of 69.2% current assets and 30.8% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 27.8% |
| Accounts Receivable | Skr2.68 Million | 20.3% |
| Inventory | Skr2.79 Million | 21.2% |
| Property, Plant & Equipment | Skr119.00K | 0.9% |
| Intangible Assets | Skr3.79 Million | 28.7% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Scandinavian ChemoTech AB Series B's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Scandinavian ChemoTech AB Series B working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Scandinavian ChemoTech AB Series B's current assets represent 69.2% of total assets in 2025, a decrease from 100.0% in 2013.
- Cash Position: Cash and equivalents constituted 27.8% of total assets in 2025, down from 100.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 28.0% of total assets, an increase from 0.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 28.7% of total assets.
Scandinavian ChemoTech AB Series B Competitors by Total Assets
Key competitors of Scandinavian ChemoTech AB Series B based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩12.65 Trillion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Immunovant Inc
NASDAQ:IMVT
|
USA | $852.49 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
Scandinavian ChemoTech AB Series B - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.81 | 0.76 | 11.12 |
| Quick Ratio | 0.52 | 0.43 | 10.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr-1.78 Million | Skr-2.43 Million | Skr16.67 Million |
Scandinavian ChemoTech AB Series B - Advanced Valuation Insights
This section examines the relationship between Scandinavian ChemoTech AB Series B's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 47.43 |
| Latest Market Cap to Assets Ratio | 0.66 |
| Asset Growth Rate (YoY) | -1.3% |
| Total Assets | Skr13.20 Million |
| Market Capitalization | $8.71 Million USD |
Valuation Analysis
Below Book Valuation: The market values Scandinavian ChemoTech AB Series B's assets below their book value (0.66x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Scandinavian ChemoTech AB Series B's assets decreased by 1.3% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Scandinavian ChemoTech AB Series B (2013–2025)
The table below shows the annual total assets of Scandinavian ChemoTech AB Series B from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr13.20 Million ≈ $1.42 Million |
-1.35% |
| 2024-12-31 | Skr13.38 Million ≈ $1.44 Million |
-10.01% |
| 2023-12-31 | Skr14.87 Million ≈ $1.60 Million |
-31.48% |
| 2022-12-31 | Skr21.70 Million ≈ $2.34 Million |
-15.92% |
| 2021-12-31 | Skr25.81 Million ≈ $2.78 Million |
+61.40% |
| 2020-12-31 | Skr15.99 Million ≈ $1.72 Million |
-8.57% |
| 2019-12-31 | Skr17.49 Million ≈ $1.88 Million |
-23.32% |
| 2018-12-31 | Skr22.81 Million ≈ $2.45 Million |
+77.58% |
| 2017-12-31 | Skr12.84 Million ≈ $1.38 Million |
-23.67% |
| 2016-12-31 | Skr16.83 Million ≈ $1.81 Million |
+152.93% |
| 2015-12-31 | Skr6.65 Million ≈ $715.95K |
+9995.57% |
| 2014-12-31 | Skr65.90K ≈ $7.09K |
+48.40% |
| 2013-12-31 | Skr44.41K ≈ $4.78K |
-- |
About Scandinavian ChemoTech AB Series B
Neem's Hill AB, a medical technology company, engages in the development of patented treatment alternatives for humans and animals with cancer in Sweden and internationally. It offers IQwave, an electroporation that generates tumor-specific electrical stimulation for the treatment of solid superficial tumors of various sizes and locations. Neem's Hill AB was formerly known as Scandinavian ChemoTe… Read more